ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Effect and mechanism of Lycium barbarum polysaccharide on gastrointestinal motility in slow transit constipation.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protective effects of medicinal plant-derived metabolites on slow transit constipation via the ENS-ICC-SMC pathway.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Slow transit constipation (STC) seriously affects the physical and mental health of patients. While the active ingredients of traditional Chinese medicine (TCM) are widely used in the treatment of STC due to their low toxicity and side effects, the aim of this study was to investigate the effect of Lycium barbarum polysaccharide (LBP) on STC. The STC mouse model was induced by the compound diphenoxylate. Defecation, fecal moisture, and weight loss of the STC models were monitored. Gastrointestinal (GI) motility was assessed by intestinal propulsive rate, and enzyme-linked immunosorbent assay (ELISA) kits were used to analyze the levels of substance P (SP) and vasoactive intestinal peptide (VIP). The expression levels of inflammatory cytokines (Tnf-α, Il-6, and Il-1β), stem cell factor receptor (C-kit), stem cell factor (Scf), Bcl-2, Bax, and Caspase-3 were evaluated by qRT-PCR. The defecation, fecal moisture, and body weight of mice with STC were significantly improved by LBP, and LBP increased the intestinal propulsive rate of STC, increased the secretion of SP, and decreased the secretion of VIP. The intervention of LBP further suppressed the expression levels of Tnf-α, Il-6, and Il-1β in STC. LBP promoted the expression of the C-kit, Scf, and Bcl-2 and inhibited the expression of Bax and Caspase-3. LBP may alleviate symptoms of slow transit constipation (STC) and enhance gastrointestinal motility by modulating gastrointestinal hormone levels, promoting proliferation, and inhibiting the apoptosis of interstitial cells of Cajal (ICCs).
Indexed as
Identifiers
39305326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.